Nontuberculous Mycobacterium Treatment Market Size [2031]
Nontuberculous Mycobacterium Treatment Market Size [2031]
Segments - Nontuberculous Mycobacterium Treatment Market by Drug Type (Azithromycin, Clarithromycin, Rifampin, Rifabutin, Ethambutol, Streptomycin, and Amikacin), End-user (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size,Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-6083
| 4.7 Rating
| 58 Reviews
| 197 Pages
| Format :
Report Description
Nontuberculous Mycobacterium Treatment Market Outlook 2031
The global nontuberculous mycobacterium treatment market size was USD 12 Bn in 2022 and is likely to reach USD 20 Bn by 2031, expanding at a CAGR of 5.5% during 2023–2031. The market growth is attributed to the growing elderly and vulnerable population.
The unprecedented growth in the immuno compromised population has boosted the market significantly. A large number of immuno compromised, elderly individuals is susceptible to respiratory illnesses, due to an increase in life expectancy rates. For instance,
-
According to a March 2020 report published in the International Journal of Infectious Diseases, nontuberculous mycobacterium infections are prevalent in the geriatric population, young children, and HIV-infected patients.
Advancements in medical sciences have led to the development of complex medical and surgical procedures as well as the awareness and recognition of skilled medical professionals. According to a March 2020 report published in the International Journal of Infectious Diseases, the recent advances in DNA sequencing are projected to revolutionize the diagnostic capacities of the infection.
The COVID-19 pandemic boosted the market considerably, owing to the rapid spread of infection among people. A large number of patients were complaining about breathing problems and coughing and extensive checkup was required. Most professionals were recruited to treat patients suffering from the virus and large sums of money were being invested to ensure proper recovery of patients. Post pandemic, the market is expected to grow at a significant pace.
Impact of Artificial Intelligence (AI) in Nontuberculous Mycobacterium Treatment Market
Growing use of Artificial Intelligence (AI) is projected to revolutionize the market over the forecast period. Most antibiotics used to treat the nontuberculous mycobacterium are proving to be in effective, owing to the rise in antibiotic resistance. Thus, AI is increasingly being used to gather data to create effective antibiotics to treat this infection. According to a June 2022 report published by the National Institutes of Health, IDentfi.AI, an AI program, was used to create highly effective drug combinations to treat this infection.
Nontuberculous Mycobacterium Treatment Market Dynamics
Drivers
Growing percentage of the vulnerable, elderly population is driving the market. The growth of the geriatric, immuno compromised populationis leading to an increasing focus on healthcare solutions. This is resulting in easy access to sub sidized healthcare and modern medical equipment. These factors are expected to boost the market in the coming years. For instance,
-
According to a March 2020 report published by the National Institutes of Health, nontuberculous mycobacterium is highly resistant to antibiotics. Therefore, researchers globally are turning to complex diagnostic tools for the early detection of the infection.
Restraints
High cost of treatment procedures is expected to hinder the market over the coming years. Most people do not have access to subsidized, advanced medical procedures, due to the expensive treatment procedures and lack of medical awareness in low-income regions. This is likely to hamper the market growth.
-
According to a March 2020 report by the International Journal of Infectious Diseases, treatment procedures are generally available in high-income regions, such as North America and Europe but are significantly underdeveloped in low-income regions. This disparity is expected to hinder the market growth considerably.
Emerging Opportunities
Developments in stem cell research and DNA sequencing techniques are projected to revolutionize the market over the coming years. Focus on effective techniques to cure nanotuberculosis mycobacterium infection is growing, due to the ever-increasing problem of antibiotic resistance. Growing R&D investments and the use of advanced epigenetic tools such as CRISPR makes the treatment simple and effective. This is expected to create lucrative opportunities for the market growth.
Scope of the Nontuberculous Mycobacterium Treatment Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Nontuberculous Mycobacterium Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2020–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Drug Type (Azithromycin; Clarithromycin; Rifampin; Rifabutin; Ethambutol; Streptomycin; and Amikacin) and End-user (Hospital Pharmacies; Retail Pharmacies; Online Pharmacies) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, MarketTrends, and Revenue Forecast |
|
Key Players Covered in the Report |
Atara Biotherapeutics, Inc.; Beyond Air Inc.; GSK plc.; Insmed Incorporated. ; Novartis AG; RedHill Biopharma Ltd.; Savara Inc.; and TFF Pharmaceuticals |
Market Segment Insights
Drug Type Segment Analysis
Based on drug type, the nontuberculous mycobacterium treatment market is divided into azithromycin, clarithromycin, rifampin, rifabutin, ethambutol, streptomycin, and amikacin. The clarithromycin segment is projected to expand at a significant growth rate during the projection period, owing to its improved efficacy and few side effects. Additionally, this drug is highly versatile and is used to treat anything from heart problems to severe lung infections. Hence, this segment occupies a majority of the market share.
The azithromycin segment is projected to expand ata considerable CAGR over the forecast period, owing to significant to lerability and short-duration doses. Several medical professionals recommend the oral dosage of this drug, due to its effectiveness. Therefore, its popularity is expected to grow considerably over the coming years.
End-user Segment Analysis
On the basis of end-user, the global market is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to dominate the market during the forecast period, owing to the easy availability of a wide variety of drugs and medications in hospitals. They have high access to highly effective, latest medications. As a result, this segment is likely to hold a major share of the market.
The online pharmacies segment is projected to expand ata considerable CAGR over the forecast period, owing to the increasing digitization of industries. Many businesses have begun selling products online as well as offline, and the medical industry has also adopted this practice. As a result, the number of online pharmacies is growing constantly. This growth is expected to persist over the coming years.
Regional Outlook
In terms of region, the global nontuberculous mycobacterium treatment market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America is expected to dominate the market during the projection period,owing to highaccess to advanced medical treatments and skilled medical personnel in the region. A majority of cutting-edge techniques such as DNA modification and stem cell research arebeing conducted in the US. These tools are highly valuable and are proven to be effective in treating nontuberculous mycobacterium infections and are thus projected to boost the market.
The market in Asia Pacific is projected to expand at a considerable CAGR, owing to the rapid expansion and development of the medical sector in this region. This growth rate is projected to remain steady across the forecast period. It is especially visible in the high-income countries of Japan and Singapore; however, it is also noticeable in the low/middle-income countriesof China and India.
Segments
The nontuberculous mycobacterium treatment market has been segmented based on
Drug Type
- Azithromycin
- Clarithromycin
- Rifampin
- Rifabutin
- Ethambutol
- Streptomycin
- Amikacin
End-user
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Atara Biotherapeutics, Inc.
- Beyond Air Inc.
- GSK plc.
- Insmed Incorporated.
- Novartis AG
- RedHill Biopharma Ltd.
- Savara Inc.
- TFF Pharmaceuticals
Competitive Landscape
Key players competing in the global nontuberculous mycobacterium treatment market are Atara Biotherapeutics, Inc.; Beyond Air Inc.; GSK plc.; Insmed Incorporated. ; Novartis AG; RedHill Biopharma Ltd.; Savara Inc.; and TFF Pharmaceuticals.
These companies implementeddynamic strategies, including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion, to expand their consumer base worldwide. For instance,
In August 2023, Atara Biotherapeutics, Inc. created a unique platform to develop novel treatments for individuals suffering from cancer as well as other auto immune diseases. This platform is projected to provide transformative therapies to patients suffering from serious diseases.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Nontuberculous Mycobacterium Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nontuberculous Mycobacterium Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nontuberculous Mycobacterium Treatment Market - Supply Chain
4.5. Global Nontuberculous Mycobacterium Treatment Market Forecast
4.5.1. Nontuberculous Mycobacterium Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nontuberculous Mycobacterium Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Nontuberculous Mycobacterium Treatment Market Absolute $ Opportunity
5. Global Nontuberculous Mycobacterium Treatment Market Analysis and Forecast by End Users
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by End Users
5.2.2. Y-o-Y Growth Projections by End Users
5.3. Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by End Users
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies
5.3.3. Online Pharmacies
5.4. Absolute $ Opportunity Assessment by End Users
5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Nontuberculous Mycobacterium Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Nontuberculous Mycobacterium Treatment Demand Share Forecast, 2019-2026
7. North America Nontuberculous Mycobacterium Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by End Users
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
7.5. Basis Point Share (BPS) Analysis by End Users
7.6. Y-o-Y Growth Projections by End Users
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Nontuberculous Mycobacterium Treatment Demand Share Forecast, 2019-2026
8. Latin America Nontuberculous Mycobacterium Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by End Users
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Basis Point Share (BPS) Analysis by End Users
8.6. Y-o-Y Growth Projections by End Users
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Nontuberculous Mycobacterium Treatment Demand Share Forecast, 2019-2026
9. Europe Nontuberculous Mycobacterium Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by End Users
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by End Users
9.6. Y-o-Y Growth Projections by End Users
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Nontuberculous Mycobacterium Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Nontuberculous Mycobacterium Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by End Users
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by End Users
10.6. Y-o-Y Growth Projections by End Users
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Nontuberculous Mycobacterium Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Nontuberculous Mycobacterium Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Nontuberculous Mycobacterium Treatment Market Size and Volume Forecast by End Users
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by End Users
11.6. Y-o-Y Growth Projections by End Users
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Nontuberculous Mycobacterium Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Nontuberculous Mycobacterium Treatment Market: Market Share Analysis
12.2. Nontuberculous Mycobacterium Treatment Distributors and Customers
12.3. Nontuberculous Mycobacterium Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Atara Biotherapeutics, Inc.
12.4.2. Beyond Air Inc.
12.4.3. GSK plc.
12.4.4. Insmed Incorporated.
12.4.5. Novartis AG
12.4.6. RedHill Biopharma Ltd.
12.4.7. Savara Inc.
12.4.8. TFF Pharmaceuticals
Methodology
Related Reports
Some other reports from this category!
Our Clients
